BAIAP2

Summary

BAIAP2 (BAR/IMD domain containing adaptor protein 2, HGNC:947) is a protein-coding gene on chromosome 17q25.3, encoding BAR/IMD domain-containing adapter protein 2 (Q9UQB8). Adapter protein that links membrane-bound small G-proteins to cytoplasmic effector proteins.

The protein encoded by this gene has been identified as a brain-specific angiogenesis inhibitor (BAI1)-binding protein. This adaptor protein links membrane bound G-proteins to cytoplasmic effector proteins. This protein functions as an insulin receptor tyrosine kinase substrate and suggests a role for insulin in the central nervous system. It also associates with a downstream effector of Rho small G proteins, which is associated with the formation of stress fibers and cytokinesis. This protein is involved in lamellipodia and filopodia formation in motile cells and may affect neuronal growth-cone guidance. This protein has also been identified as interacting with the dentatorubral-pallidoluysian atrophy gene, which is associated with an autosomal dominant neurodegenerative disease. Alternative splicing results in multiple transcript variants encoding distinct isoforms.

Source: NCBI Gene 10458 — RefSeq curated summary.

At a glance

• GWAS associations: 13
• Clinical variants (ClinVar): 128 total — 7 pathogenic
• Phenotypes (HPO): 43
• MANE Select transcript: NM_001144888

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:947
Approved symbol	BAIAP2
Name	BAR/IMD domain containing adaptor protein 2
Location	17q25.3
Locus type	gene with protein product
Status	Approved
Aliases	BAP2, IRSp53, WAML
Ensembl gene	ENSG00000175866
Ensembl biotype	protein_coding
OMIM	605475
Entrez	10458

Gene structure

Transcript identifiers

Ensembl transcripts: 32 — 19 protein_coding, 6 protein_coding_CDS_not_defined, 4 retained_intron, 3 nonsense_mediated_decay

ENST00000321280, ENST00000321300, ENST00000416299, ENST00000428708, ENST00000435091, ENST00000570913, ENST00000571530, ENST00000572073, ENST00000572329, ENST00000572498, ENST00000572918, ENST00000573017, ENST00000573659, ENST00000573677, ENST00000573894, ENST00000574027, ENST00000574688, ENST00000574804, ENST00000575245, ENST00000575712, ENST00000575750, ENST00000575841, ENST00000575958, ENST00000575989, ENST00000576225, ENST00000576364, ENST00000576470, ENST00000576756, ENST00000576995, ENST00000577097, ENST00000892758, ENST00000892759

RefSeq mRNA: 35 — MANE Select: NM_001144888 NM_001144888, NM_001385127, NM_001385128, NM_001385129, NM_001385130, NM_001385131, NM_001385132, NM_001385133, NM_001385134, NM_001385135, NM_001385136, NM_001385137, NM_001385138, NM_001385139, NM_001385140, NM_001385141, NM_001385144, NM_001385145, NM_001385146, NM_001385147, NM_001385148, NM_001385149, NM_001385150, NM_001385151, NM_001385152, NM_001385153, NM_001385154, NM_001385155, NM_001385156, NM_001385157, NM_001385158, NM_001385159, NM_006340, NM_017450, NM_017451

CCDS: CCDS11775, CCDS11776, CCDS11777, CCDS45806, CCDS92414

Canonical transcript exons

ENST00000428708 — 14 exons

Exon	Start	End
ENSE00003466896	81106078	81106146
ENSE00003479422	81084832	81084893
ENSE00003497796	81115770	81117434
ENSE00003514272	81106745	81106907
ENSE00003516981	81103907	81104108
ENSE00003523082	81057881	81057967
ENSE00003530857	81035151	81035308
ENSE00003538981	81085654	81085725
ENSE00003549369	81086443	81086580
ENSE00003563807	81104514	81104715
ENSE00003581261	81108475	81108509
ENSE00003608451	81053668	81053743
ENSE00003657546	81099928	81100080
ENSE00003693124	81103502	81103723

Expression profiles

Bgee: expression breadth ubiquitous, 256 present calls, max score 99.12.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 27.5618 / max 873.6556, expressed in 1770 samples.

FANTOM5 promoters (13 alternative TSS)

Promoter ID	TPM avg	Samples expressed
163284	24.1979	1760
163292	1.1874	632
163293	1.1603	620
163286	0.2218	69
163296	0.1918	86
163295	0.1317	55
163297	0.1049	38
163287	0.1044	46
163294	0.0782	44
163290	0.0733	31

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
Brodmann (1909) area 10	UBERON:0013541	99.12	gold quality
frontal pole	UBERON:0002795	99.10	gold quality
lower esophagus mucosa	UBERON:0035834	98.50	gold quality
middle frontal gyrus	UBERON:0002702	98.42	gold quality
right frontal lobe	UBERON:0002810	98.26	gold quality
skin of abdomen	UBERON:0001416	98.06	gold quality
anterior cingulate cortex	UBERON:0009835	97.98	gold quality
skin of leg	UBERON:0001511	97.96	gold quality
cingulate cortex	UBERON:0003027	97.95	gold quality
Brodmann (1909) area 9	UBERON:0013540	97.53	gold quality
caudate nucleus	UBERON:0001873	97.30	gold quality
nucleus accumbens	UBERON:0001882	97.27	gold quality
esophagus mucosa	UBERON:0002469	97.24	gold quality
prefrontal cortex	UBERON:0000451	96.98	gold quality
right lung	UBERON:0002167	96.95	gold quality
right hemisphere of cerebellum	UBERON:0014890	96.94	gold quality
oocyte	CL:0000023	96.89	gold quality
putamen	UBERON:0001874	96.79	gold quality
paraflocculus	UBERON:0005351	96.73	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	96.57	gold quality
cerebellar hemisphere	UBERON:0002245	96.49	gold quality
amygdala	UBERON:0001876	96.46	gold quality
cerebellar cortex	UBERON:0002129	96.44	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	96.39	gold quality
adenohypophysis	UBERON:0002196	96.29	gold quality
neocortex	UBERON:0001950	96.25	gold quality
right uterine tube	UBERON:0001302	96.24	gold quality
frontal cortex	UBERON:0001870	96.17	gold quality
sural nerve	UBERON:0015488	96.17	gold quality
right lobe of liver	UBERON:0001114	96.08	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

50 targeting BAIAP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-4525	99.94	64.38	675
HSA-MIR-5010-5P	99.94	64.11	705
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-4779	99.86	66.50	1583
HSA-MIR-5010-3P	99.83	70.60	2357
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311
HSA-MIR-6779-5P	99.70	65.76	2363
HSA-MIR-6512-3P	99.65	66.07	1468
HSA-MIR-6720-5P	99.65	66.22	1459
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-6740-3P	99.48	68.49	1392
HSA-MIR-6722-3P	99.45	67.62	1919
HSA-MIR-940	99.37	66.14	2064
HSA-MIR-6808-5P	99.31	66.23	2150
HSA-MIR-6893-5P	99.31	66.25	2119
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-6799-5P	99.14	65.72	2093
HSA-MIR-1909-3P	99.03	66.56	1662
HSA-MIR-939-3P	98.97	65.07	2347

Literature-anchored findings (GeneRIF, showing 40)

• LIN7B is a partner of IRSp53 anchoring the actin-based membrane cytoskeleton at cell-cell contacts. (PMID:14596909)
• IRSp53, when activated by small GTPases, participates in F-actin reorganization not only in an SH3-dependent manner but also in a manner dependent on the activity of the IRSp53/MIM homology domain (PMID:14752106)
• IRSp53 comprises a central SH3 domain, which binds to proline-rich regions of a wide range of actin regulators, and a conserved N-terminal IRSp53/MIM homology domain that harbours F-actin-bundling activity. Presents crystal structure of this novel domain (PMID:15635447)
• These results suggest that PSD-95 interaction is an important determinant of synaptic IRSp53 localization and that the SH3 domain of IRSp53 links activated Rac1/Cdc42 to downstream effectors for the regulation of spine morphogenesis. (PMID:15673667)
• Therefore, IRSp53 optimizes the activity of the WAVE2 complex in the presence of activated Rac and PIP(3). (PMID:16702231)
• The mechanism of membrane deforamtion induced by the IRSp53 RCB domain is reported. (PMID:17003044)
• These results support a model whereby the synergic bundling activity of the IRSp53-Eps8 complex, regulated by Cdc42, contributes to the generation of actin bundles, thus promoting filopodial protrusions. (PMID:17115031)
• Together, these data reveal that interplay between actin dynamics and a novel membrane-deformation activity promotes cell motility and morphogenesis. (PMID:17371834)
• tyrosine 310 as a primary site of tyrosine phosphorylation in response to insulin signalling and we have shown that although IRSp53 is tyrosine phosphorylated in response to epidermal growth factor receptor signalling, tyrosine 310 is not crucial. (PMID:18417251)
• LIN7-IRSp53 association plays a role during assembly of functional tight junctions and surface polarization in epithelial cells (PMID:19054385)
• Both spatial learning and novel object recognition are impaired in transgenic mice deficient of IRSp53 expression. (PMID:19193906)
• The authors show that IRSp53 family members, key regulators of membrane and actin dynamics, directly interact with both Tir and EspF(U).[Tir & EspFU] (PMID:19286134)
• SPIN90 and IRSp53 positively cooperated to mediate Rac activation, and co-expression of SPIN90 and IRSp53 in COS-7 cells led to the complex formation of SPIN90-IRSp53 in the leading edge of cells (PMID:19460367)
• this study support the participation of BAIAP2 in the continuity of ADHD across life span,in some of the populations analyzed, suggest that genetic factors potentially influencing abnormal cerebral lateralization may be involved in this disorder. (PMID:19733838)
• The authors demonstrated that the association between the enterohemorrhagic Escherichia coli O157:H7 EspFu and IRSp53 induces dynamic membrane remodeling in epithelial cells. (PMID:19762983)
• this work does not conform to current views that the inverse-BAR domain or Cdc42 controls IRSp53 localization but provides an alternative model of how IRSp53 is recruited (and released) to carry out its functions at lamellipodia and filopodia. (PMID:19933840)
• IRSp53 and spinophilin regulate localized Rac activation by T-lymphocyte invasion and metastasis protein 1 (PMID:20360004)
• IRSp53, through its interaction with Eps8, not only affects cell migration but also dictates cellular growth in cancer cells. (PMID:20418908)
• Suppression of IRSp53 expression inhibited IGF-I-induced membrane targeting and local accumulation of WAVE2 at the leading edge of cells. (PMID:20621182)
• Cdc42 regulates the activity of IRSp53 by regulating the IRSp53-WIRE interaction as well as localization of the complex to plasma membrane to generate filopodia. (PMID:20678498)
• The results of this study and the supporting evidence highlighted previously suggest that the BAIAP2 gene may be involved in autism susceptibility. (PMID:20888579)
• A molecular dynamics study of the interaction between domain I-BAR of the IRSp53 protein and negatively charged membranes (PMID:21542353)
• Studied generation of filopodia with regards to the dynamic interaction established by Eps8, IRSp53 and VASP with actin filaments. (PMID:21814501)
• Structural basis for complex formation between human IRSp53 and the translocated intimin receptor Tir of enterohemorrhagic E. coli (PMID:21893288)
• mDia1 and WAVE2 are important Src homology 3 domain partners of IRSp53 in forming filopodia. (PMID:22179776)
• LIN7 is a novel regulator of IRSp53. (PMID:22767515)
• These above results indicated the possible involvement of BAIAP2 in the etiology of attention deficit disorder with hyperactivity, especially ADHD-I. (PMID:24377651)
• BAIAP2 is related to emotional modulation of human memory strength. (PMID:24392092)
• IRSp53 adopts a closed inactive conformation that opens synergistically with the binding of human Cdc42 to the CRIB-PR and effector proteins, such as the tumor-promoting factor Eps8, to the SH3 domain. (PMID:24584464)
• determined the alpha-synuclein-binding domain of beta-III tubulin and demonstrated that a short fragment containing this domain can suppress alpha-synuclein accumulation in the primary cultured cells (PMID:25031323)
• Results suggest the hypothesis that defective actin/membrane modulation in IRSp53-deficient dendritic spines may lead to social and cognitive deficits through N-methyl-d-aspartate receptor dysfunction. (PMID:26275848)
• dimers sense negative membrane curvature, display a non-monotonic sorting with curvature, and expand the membrane tube at high imposed tension while constricting it at low tension (PMID:26469246)
• Overexpression of LIN7 or IRSp53 did not prevent the formation of hyperfused mitochondria in cells coexpressing the Drp1 K38A mutant, thus suggesting that LIN7-IRSp53 complex requires functional Drp1 to regulate mitochondrial morphology. (PMID:27320196)
• BAIAP2 is a candidate gene for mediating dendritic spine density abnormalities in schizophrenia. Data suggest that altered DNA methylation in schizophrenia may be a mechanism for schizophrenia-related dendritic spine density reductions. (PMID:28195572)
• A BAIAP2 polymorphism, rs8079626, affects medial frontal gyrus and inferior parietal lobe connectivity in attention deficit hyperactivity order adults. (PMID:28938222)
• Coincident with the loss of PICK1 by GBF1-activated ARF1, CDC42 recruitment leads to the activation of IRSp53 and the ARP2/3 complex, resulting in a burst of F-actin polymerisation potentially powering scission. (PMID:29743604)
• IRSp53 heterodimer with only one subunit is phosphorylated, and each subunit of IRSp53 independently binds one 14-3-3 dimer. (PMID:30696821)
• Phosphorylation-dependent inhibition of IRSp53 by 14-3-3 counters activation by Cdc42 and cytoskeletal effectors, resulting in down-regulation of filopodia dynamics and cancer cell migration. In serum-starved cells, increased IRSp53 phosphorylation triggers 14-3-3 binding, which inhibits filopodia formation and dynamics, irrespective of whether IRSp53 is activated by Cdc42 or downstream effectors (Eps8, Ena/VASP). (PMID:30893014)
• BAIAP2 rs8079781, postnatal smoking exposure, and emotional problems in Japanese children aged 5 years: the Kyushu Okinawa Maternal and Child Health Study. (PMID:32388796)
• IRSp53 is a novel interactor of SHIP2: A role of the actin binding protein Mena in their cellular localization in breast cancer cells. (PMID:32535200)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	baiap2a	ENSDARG00000062799
danio_rerio	baiap2b	ENSDARG00000103333
mus_musculus	Baiap2	ENSMUSG00000025372
rattus_norvegicus	Baiap2	ENSRNOG00000004049
drosophila_melanogaster	IRSp53	FBGN0052082

Paralogs (2): BAIAP2L1 (ENSG00000006453), BAIAP2L2 (ENSG00000128298)

Protein

Protein identifiers

BAR/IMD domain-containing adapter protein 2 — Q9UQB8 (reviewed: Q9UQB8)

Alternative names: Brain-specific angiogenesis inhibitor 1-associated protein 2, Fas ligand-associated factor 3, Insulin receptor substrate p53/p58, Insulin receptor substrate protein of 53 kDa

All UniProt accessions (16): B4DWA1, Q9UQB8, I3L0M4, I3L0Y9, I3L113, I3L125, I3L1C8, I3L2J6, I3L2M4, I3L327, I3L3C5, I3L3C6, I3L3J7, I3L4A3, I3L4C2, I3L526

UniProt curated annotations — full annotation on UniProt →

Function. Adapter protein that links membrane-bound small G-proteins to cytoplasmic effector proteins. Necessary for CDC42-mediated reorganization of the actin cytoskeleton and for RAC1-mediated membrane ruffling. Involved in the regulation of the actin cytoskeleton by WASF family members and the Arp2/3 complex. Plays a role in neurite growth. Acts syngeristically with ENAH to promote filipodia formation. Plays a role in the reorganization of the actin cytoskeleton in response to bacterial infection. Participates in actin bundling when associated with EPS8, promoting filopodial protrusions.

Subunit / interactions. Homodimer. Interacts with CDC42 and RAC1 that have been activated by GTP binding. Interacts with ATN1, ADGRB1, EPS8, SHANK1, SHANK2, SHANK3, WASF1 and WASF2. Interacts with ENAH after recruitment of CDC42. Interacts with TIAM1 and DIAPH1. Interacts (via SH3 domain) with E.coli effector protein EspF(U) (via PXXP motifs). Interacts with E.coli intimin receptor Tir.

Subcellular location. Cytoplasm. Membrane. Cell projection. Filopodium. Ruffle. Cytoskeleton.

Tissue specificity. Isoform 1 and isoform 4 are expressed almost exclusively in brain. Isoform 4 is barely detectable in placenta, prostate and testis. A short isoform is ubiquitous, with the highest expression in liver, prostate, testis and placenta.

Post-translational modifications. Phosphorylated on tyrosine residues by INSR in response to insulin treatment.

Domain organisation. The IMD domain forms a coiled coil. The isolated domain can induce actin bundling and filopodia formation. In the absence of G-proteins intramolecular interaction between the IMD and the SH3 domain gives rise to an auto-inhibited state of the protein. Interaction of the IMD with RAC1 or CDC42 leads to activation. The SH3 domain interacts with ATN1, ADGRB1, WASF1, WASF2, SHANK1, DIAPH1 and ENAH.

Isoforms (6)

UniProt ID	Names	Canonical?
Q9UQB8-1	1, IRSp53(L)	yes
Q9UQB8-2	2
Q9UQB8-3	3
Q9UQB8-4	4, BAIAP2-alpha
Q9UQB8-5	5, BAIAP2-beta
Q9UQB8-6	6

RefSeq proteins (35): NP_001138360, NP_001372056, NP_001372057, NP_001372058, NP_001372059, NP_001372060, NP_001372061, NP_001372062, NP_001372063, NP_001372064, NP_001372065, NP_001372066, NP_001372067, NP_001372068, NP_001372069, NP_001372070, NP_001372073, NP_001372074, NP_001372075, NP_001372076, NP_001372077, NP_001372078, NP_001372079, NP_001372080, NP_001372081, NP_001372082, NP_001372083, NP_001372084, NP_001372085, NP_001372086, NP_001372087, NP_001372088, NP_006331, NP_059344, NP_059345 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001452	SH3_domain	Domain
IPR013606	I-BAR_dom	Domain
IPR027267	AH/BAR_dom_sf	Homologous_superfamily
IPR027681	IRSp53/IRTKS/Pinkbar	Family
IPR030128	BAIP2_I-BAR_dom	Domain
IPR035594	BAIP2_SH3	Domain
IPR036028	SH3-like_dom_sf	Homologous_superfamily

Pfam: PF07653, PF08397

UniProt features (59 total): modified residue 12, helix 9, mutagenesis site 8, strand 7, splice variant 5, turn 4, region of interest 3, sequence conflict 3, compositionally biased region 3, domain 2, chain 1, sequence variant 1, coiled-coil region 1

Structure

Experimental structures (PDB)

12 structures.

PDB	Method	Resolution (Å)
6ZEG	X-RAY DIFFRACTION	1.09
6ZEI	X-RAY DIFFRACTION	1.39
3RNJ	X-RAY DIFFRACTION	1.5
4JS0	X-RAY DIFFRACTION	1.9
6BCR	X-RAY DIFFRACTION	1.99
2YKT	X-RAY DIFFRACTION	2.11
1Y2O	X-RAY DIFFRACTION	2.2
6BCY	X-RAY DIFFRACTION	2.3
6BD1	X-RAY DIFFRACTION	2.35
1WDZ	X-RAY DIFFRACTION	2.63
6BQT	X-RAY DIFFRACTION	2.8
6BD2	X-RAY DIFFRACTION	2.9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UQB8-F1	72.81	0.52

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (12): 261, 296, 323, 325, 336, 340, 346, 360, 366, 384, 395, 454

Mutagenesis-validated functional residues (8):

Position	Phenotype
142	abolishes actin-bundling and filopodia formation; when associated with e-143; e-146 and e147.
143	abolishes actin-bundling and filopodia formation; when associated with e-142; e-146 and e147.
146	abolishes actin-bundling and filopodia formation; when associated with e-142; e-143 and e147.
147	abolishes actin-bundling and filopodia formation; when associated with e-142; e-143 and e146.
267	loss of interaction with cdc42. loss of stimulation of neurite growth.
413	impairs the sh3 domain and abolishes the interaction with eps8.
427	loss of interaction with enah and no induction of filopodia; when associated with a-428.
428	loss of interaction with enah and no induction of filopodia; when associated with a-427.

Function

Pathways and Gene Ontology

Reactome pathways

23 pathways

ID	Pathway
R-HSA-2029482	Regulation of actin dynamics for phagocytic cup formation
R-HSA-4420097	VEGFA-VEGFR2 Pathway
R-HSA-5663213	RHO GTPases Activate WASPs and WAVEs
R-HSA-9013148	CDC42 GTPase cycle
R-HSA-9013149	RAC1 GTPase cycle
R-HSA-9013423	RAC3 GTPase cycle
R-HSA-9664422	FCGR3A-mediated phagocytosis
R-HSA-162582	Signal Transduction
R-HSA-1643685	Disease
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System
R-HSA-194138	Signaling by VEGF
R-HSA-194315	Signaling by Rho GTPases
R-HSA-195258	RHO GTPase Effectors
R-HSA-2029480	Fcgamma receptor (FCGR) dependent phagocytosis
R-HSA-5663205	Infectious disease
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases
R-HSA-9012999	RHO GTPase cycle
R-HSA-9658195	Leishmania infection
R-HSA-9664407	Parasite infection
R-HSA-9664417	Leishmania phagocytosis
R-HSA-9716542	Signaling by Rho GTPases, Miro GTPases and RHOBTB3
R-HSA-9824443	Parasitic Infection Pathways

MSigDB gene sets: 408 (showing top): BIOCARTA_RHO_PATHWAY, GOBP_DENDRITE_DEVELOPMENT, TGGTGCT_MIR29A_MIR29B_MIR29C, AGGAAGC_MIR5163P, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_REGULATION_OF_PROTEIN_POLYMERIZATION, GOBP_ACTIN_FILAMENT_BUNDLE_ORGANIZATION, REACTOME_INNATE_IMMUNE_SYSTEM, HNF3ALPHA_Q6, GOBP_REGULATION_OF_CELL_MORPHOGENESIS, GOBP_RESPONSE_TO_ACID_CHEMICAL, GOCC_SECRETORY_GRANULE, GOBP_REGULATION_OF_DENDRITE_MORPHOGENESIS, GOBP_DENDRITIC_SPINE_DEVELOPMENT, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP

GO Biological Process (21): plasma membrane organization (GO:0007009), axonogenesis (GO:0007409), insulin receptor signaling pathway (GO:0008286), regulation of cell shape (GO:0008360), dendrite development (GO:0016358), positive regulation of actin filament polymerization (GO:0030838), regulation of actin cytoskeleton organization (GO:0032956), protein localization to synapse (GO:0035418), regulation of synaptic plasticity (GO:0048167), actin filament bundle assembly (GO:0051017), actin crosslink formation (GO:0051764), positive regulation of dendritic spine morphogenesis (GO:0061003), cellular response to epidermal growth factor stimulus (GO:0071364), cellular response to L-glutamate (GO:1905232), regulation of modification of postsynaptic actin cytoskeleton (GO:1905274), positive regulation of excitatory postsynaptic potential (GO:2000463), positive regulation of neuron projection development (GO:0010976), neuron differentiation (GO:0030182), modulation of chemical synaptic transmission (GO:0050804), cell-cell adhesion (GO:0098609), regulation of postsynapse organization (GO:0099175)

GO Molecular Function (8): transcription coregulator binding (GO:0001221), cytoskeletal adaptor activity (GO:0008093), PDZ domain binding (GO:0030165), identical protein binding (GO:0042802), proline-rich region binding (GO:0070064), scaffold protein binding (GO:0097110), cadherin binding involved in cell-cell adhesion (GO:0098641), protein binding (GO:0005515)

GO Cellular Component (32): ruffle (GO:0001726), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytosol (GO:0005829), microtubule (GO:0005874), plasma membrane (GO:0005886), adherens junction (GO:0005912), lamellipodium (GO:0030027), secretory granule (GO:0030141), filopodium (GO:0030175), neuronal cell body (GO:0043025), dendritic shaft (GO:0043198), neuron projection terminus (GO:0044306), excitatory synapse (GO:0060076), neuron projection branch point (GO:0061845), dendritic spine cytoplasm (GO:0061846), extracellular exosome (GO:0070062), synaptic membrane (GO:0097060), Schaffer collateral - CA1 synapse (GO:0098685), glutamatergic synapse (GO:0098978), postsynaptic density, intracellular component (GO:0099092), presynaptic cytosol (GO:0099523), postsynaptic cytosol (GO:0099524), cytoskeleton (GO:0005856), postsynaptic density (GO:0014069), actin cytoskeleton (GO:0015629), membrane (GO:0016020), cell projection (GO:0042995), neuron projection (GO:0043005), dendritic spine (GO:0043197), presynapse (GO:0098793), postsynapse (GO:0098794)

Reactome top-level categories

Rollup of top-14 pathways:

Category	Pathways
RHO GTPase cycle	3
Signaling by Rho GTPases	2
Fcgamma receptor (FCGR) dependent phagocytosis	1
Signaling by VEGF	1
RHO GTPase Effectors	1
Leishmania phagocytosis	1
Immune System	1
Signaling by Receptor Tyrosine Kinases	1
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	1
Innate Immune System	1
Disease	1
Signal Transduction	1
Parasitic Infection Pathways	1
Leishmania infection	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	6
synapse	4
protein binding	3
regulation of biological quality	2
neuron projection development	2
cell leading edge	2
plasma membrane bounded cell projection	2
neuron projection	2
endomembrane system organization	1
membrane organization	1
cell morphogenesis involved in neuron differentiation	1
neuron projection morphogenesis	1
axon development	1
cell surface receptor protein tyrosine kinase signaling pathway	1
cellular response to insulin stimulus	1
regulation of cell morphogenesis	1
anatomical structure development	1
actin filament polymerization	1
regulation of actin filament polymerization	1
positive regulation of protein polymerization	1
positive regulation of cytoskeleton organization	1
positive regulation of supramolecular fiber organization	1
actin cytoskeleton organization	1
regulation of actin filament-based process	1
regulation of cytoskeleton organization	1
protein localization to cell junction	1
modulation of chemical synaptic transmission	1
cellular component assembly	1
actin filament bundle organization	1
actin filament organization	1
positive regulation of neuron projection development	1
positive regulation of dendrite morphogenesis	1
dendritic spine morphogenesis	1
positive regulation of dendritic spine development	1
regulation of dendritic spine morphogenesis	1
response to epidermal growth factor	1
cellular response to growth factor stimulus	1
cellular response to amino acid stimulus	1
cellular response to nitrogen compound	1
cellular response to oxygen-containing compound	1

Protein interactions and networks

STRING

1796 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
BAIAP2	WASF2	Q9Y6W5	997
BAIAP2	CDC42	P21181	996
BAIAP2	EPS8	Q12929	982
BAIAP2	ADGRB1	O14514	974
BAIAP2	VASP	P50552	966
BAIAP2	DLG4	P78352	946
BAIAP2	WASL	O00401	930
BAIAP2	WAS	P42768	907
BAIAP2	WASF1	Q92558	864
BAIAP2	ABI2	Q9NYB9	861
BAIAP2	ABI1	Q8IZP0	848
BAIAP2	SHANK3	Q9BYB0	841
BAIAP2	IQSEC2	Q5JU85	827
BAIAP2	SHANK1	Q9Y566	729
BAIAP2	RAB40B	Q12829	727

IntAct

228 interactions, top by confidence:

A	B	Type	Score
EPS8	BAIAP2	psi-mi:“MI:0915”(physical association)	0.890
BAIAP2	EPS8	psi-mi:“MI:0915”(physical association)	0.890
YWHAQ	WDR62	psi-mi:“MI:0914”(association)	0.830
CAMK2G	CAMK2D	psi-mi:“MI:0914”(association)	0.810
YWHAH	ABLIM1	psi-mi:“MI:0914”(association)	0.800
BAIAP2	YWHAZ	psi-mi:“MI:0914”(association)	0.800
NHERF2	PODXL	psi-mi:“MI:0914”(association)	0.770
BAIAP2	BAIAP2	psi-mi:“MI:0915”(physical association)	0.740
EGFR	BAIAP2	psi-mi:“MI:0915”(physical association)	0.740
BAIAP2	YWHAQ	psi-mi:“MI:0914”(association)	0.740
BRK1	HSBP1	psi-mi:“MI:0914”(association)	0.740
BAIAP2	BAIAP2	psi-mi:“MI:0407”(direct interaction)	0.740
BAIAP2	RAC1	psi-mi:“MI:0914”(association)	0.730
RAC1	BAIAP2	psi-mi:“MI:0915”(physical association)	0.730
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
BAIAP2L1	BAIAP2	psi-mi:“MI:0915”(physical association)	0.710
BAIAP2	ABI1	psi-mi:“MI:0915”(physical association)	0.670
WASF1	BAIAP2	psi-mi:“MI:0915”(physical association)	0.660
BAIAP2	YWHAE	psi-mi:“MI:0915”(physical association)	0.650

BioGRID (340): BAIAP2 (Two-hybrid), BAIAP2 (Two-hybrid), BAIAP2 (Two-hybrid), BAIAP2 (Two-hybrid), PRR13 (Two-hybrid), C19orf25 (Two-hybrid), BAIAP2 (Two-hybrid), BAIAP2 (Affinity Capture-Western), BAIAP2 (Two-hybrid), BAIAP2 (Affinity Capture-MS), NCKAP1 (Affinity Capture-MS), CYFIP2 (Affinity Capture-MS), CYFIP1 (Affinity Capture-MS), EPS8 (Affinity Capture-MS), BAIAP2L1 (Affinity Capture-MS)

ESM2 similar proteins: A1A4L0, A6H6A9, B4F779, G5E8V9, O35382, O60890, O95219, P0CAX5, P53365, P53367, Q08DP6, Q28E02, Q3ZCL5, Q4V7P7, Q566W7, Q5EAD0, Q5R4C2, Q5RCW6, Q5T0N5, Q5VWJ9, Q5ZJ17, Q60437, Q62824, Q6AY65, Q6GMN2, Q6PCS4, Q6Y5D8, Q6ZQ82, Q7YQL5, Q7YQL6, Q80TY0, Q8BHY8, Q8BKX1, Q8CE50, Q8K221, Q8K3G9, Q8K3H0, Q8N6S4, Q8NEU8, Q8R511

Diamond homologs: O60861, Q3KR97, Q5EAD0, Q60437, Q6GMN2, Q8BKX1, Q9DBJ3, Q9UHR4, Q9UQB8, Q557J6, Q80Y61, Q9Z0R6

SIGNOR signaling

13 interactions.

A	Effect	B	Mechanism
PRKAA2	down-regulates	BAIAP2	phosphorylation
AMPK	down-regulates	BAIAP2	phosphorylation
BAIAP2	“up-regulates activity”	ENAH	binding
CDC42	“up-regulates activity”	BAIAP2	binding
MARK2	“down-regulates activity”	BAIAP2	phosphorylation
BAIAP2	up-regulates	WASF1	binding
RAC1	up-regulates	BAIAP2	binding
KANK1	“down-regulates activity”	BAIAP2	binding
RAC1	“up-regulates activity”	BAIAP2	binding
BAIAP2	up-regulates	Neurite_outgrowth
BAIAP2	“up-regulates activity”	WASF2	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 150 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
RHO GTPases Activate WASPs and WAVEs	17	49.5×	6e-23
Activation of BAD and translocation to mitochondria	7	48.9×	1e-09
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	7	43.1×	3e-09
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	7	43.1×	3e-09
Parasite infection	13	41.3×	2e-16
Leishmania phagocytosis	13	41.3×	2e-16
Activation of BH3-only proteins	8	36.4×	8e-10
Fcgamma receptor (FCGR) dependent phagocytosis	13	33.2×	4e-15

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of lamellipodium assembly	8	35.1×	5e-08
Rac protein signal transduction	8	32.8×	5e-08
lamellipodium assembly	6	19.4×	9e-05
positive regulation of actin filament polymerization	8	19.3×	3e-06
actin filament polymerization	5	17.6×	8e-04
protein targeting	6	16.0×	2e-04
substantia nigra development	6	16.0×	2e-04
peptidyl-tyrosine phosphorylation	5	15.4×	1e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

128 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	7
Likely pathogenic	0
Uncertain significance	77
Likely benign	10
Benign	8

Top pathogenic / likely-pathogenic (7)

Variant ID	HGVS	Classification
4685564	BAIAP2, ARG29TRP	Pathogenic
4685565	NM_001144888.2(BAIAP2):c.1088G>A (p.Arg363His)	Pathogenic
4685566	NM_001144888.2(BAIAP2):c.1019C>A (p.Thr340Lys)	Pathogenic
4685567	NM_001144888.2(BAIAP2):c.1018A>G (p.Thr340Ala)	Pathogenic
4685568	NM_001144888.2(BAIAP2):c.566A>T (p.Glu189Val)	Pathogenic
4685569	NM_001144888.2(BAIAP2):c.1019C>T (p.Thr340Ile)	Pathogenic
4685570	NM_001144888.2(BAIAP2):c.1024C>G (p.Pro342Ala)	Pathogenic

SpliceAI

4595 predictions. Top by Δscore:

Variant	Effect	Δscore
17:81035305:TAAGG:T	donor_loss	1.0000
17:81035306:AAGG:A	donor_loss	1.0000
17:81053666:A:AG	acceptor_gain	1.0000
17:81053667:G:GG	acceptor_gain	1.0000
17:81053667:GACC:G	acceptor_gain	1.0000
17:81053718:G:GT	donor_gain	1.0000
17:81053718:G:T	donor_gain	1.0000
17:81056511:G:T	donor_gain	1.0000
17:81057876:CTCA:C	acceptor_loss	1.0000
17:81057879:A:AG	acceptor_gain	1.0000
17:81057879:AG:A	acceptor_gain	1.0000
17:81057879:AGGT:A	acceptor_gain	1.0000
17:81057880:G:GT	acceptor_gain	1.0000
17:81057880:GG:G	acceptor_gain	1.0000
17:81057880:GGT:G	acceptor_gain	1.0000
17:81057880:GGTG:G	acceptor_gain	1.0000
17:81057880:GGTGT:G	acceptor_gain	1.0000
17:81084817:T:A	acceptor_gain	1.0000
17:81084822:T:TA	acceptor_gain	1.0000
17:81084891:ATGGT:A	donor_loss	1.0000
17:81084892:TGGTG:T	donor_loss	1.0000
17:81084895:TGAG:T	donor_loss	1.0000
17:81085646:A:AG	acceptor_gain	1.0000
17:81085646:AT:A	acceptor_gain	1.0000
17:81085647:T:G	acceptor_gain	1.0000
17:81085647:T:TA	acceptor_gain	1.0000
17:81085649:TCCA:T	acceptor_loss	1.0000
17:81085650:CCAG:C	acceptor_loss	1.0000
17:81085651:CAGC:C	acceptor_loss	1.0000
17:81085652:A:AC	acceptor_loss	1.0000

AlphaMissense

3528 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:81053696:T:C	L28P	1.000
17:81053716:G:T	G35W	1.000
17:81057896:C:A	A49D	1.000
17:81057917:T:C	L56P	1.000
17:81057928:G:A	G60R	1.000
17:81057928:G:C	G60R	1.000
17:81057928:G:T	G60W	1.000
17:81057929:G:A	G60E	1.000
17:81057938:C:A	A63D	1.000
17:81084883:T:C	L90P	1.000
17:81085688:T:C	L105P	1.000
17:81085709:A:T	D112V	1.000
17:81085721:T:C	L116P	1.000
17:81086513:T:C	L141P	1.000
17:81086522:T:C	L144P	1.000
17:81100010:G:C	R191P	1.000
17:81100015:C:A	R193S	1.000
17:81100016:G:C	R193P	1.000
17:81100028:T:C	L197P	1.000
17:81103535:T:A	W226R	1.000
17:81103535:T:C	W226R	1.000
17:81103537:G:C	W226C	1.000
17:81103537:G:T	W226C	1.000
17:81104589:C:A	A381D	1.000
17:81104628:T:C	L394P	1.000
17:81104634:T:C	F396S	1.000
17:81104661:T:C	L405P	1.000
17:81104681:G:C	G412R	1.000
17:81104682:G:A	G412D	1.000
17:81104682:G:T	G412V	1.000

dbSNP variants (sampled 300 via entrez): RS1000000998 (17:81050599 C>T), RS1000003985 (17:81100972 C>T), RS1000009015 (17:81083815 C>T), RS1000016524 (17:81074583 G>A), RS1000030400 (17:81050423 G>A), RS1000056858 (17:81103794 C>T), RS1000083248 (17:81073903 G>A,T), RS1000100120 (17:81061832 GTCT>G), RS1000105451 (17:81112157 C>CG), RS1000108811 (17:81046884 C>T), RS1000118436 (17:81111954 G>GC), RS1000124492 (17:81071602 G>A,C,T), RS1000144964 (17:81087801 T>TC), RS1000150392 (17:81049081 G>A), RS1000155588 (17:81071386 A>C)

Disease associations

OMIM: gene MIM:605475 | disease phenotypes: MIM:621468

GenCC curated gene-disease

Mondo (2): attention deficit-hyperactivity disorder (MONDO:0007743), developmental and epileptic encephalopathy 120 (MONDO:0980948)

Orphanet (0):

HPO phenotypes

43 total (30 of 43 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000252	Microcephaly
HP:0000718	Aggressive behavior
HP:0000729	Autistic behavior
HP:0000750	Delayed speech and language development
HP:0000752	Hyperactivity
HP:0000817	Reduced eye contact
HP:0001252	Hypotonia
HP:0001256	Mild intellectual disability
HP:0001263	Global developmental delay
HP:0001270	Motor delay
HP:0001302	Pachygyria
HP:0001310	Dysmetria
HP:0001344	Absent speech
HP:0002069	Bilateral tonic-clonic seizure
HP:0002119	Ventriculomegaly
HP:0002188	Delayed CNS myelination
HP:0002342	Moderate intellectual disability
HP:0002353	EEG abnormality
HP:0002360	Sleep disturbance
HP:0002376	Developmental regression
HP:0002384	Focal impaired awareness seizure
HP:0003593	Infantile onset
HP:0007270	Atypical absence seizure
HP:0007359	Focal-onset seizure
HP:0010819	Atonic seizure
HP:0010864	Severe intellectual disability
HP:0011097	Epileptic spasm
HP:0011147	Typical absence seizure
HP:0011344	Severe global developmental delay

GWAS associations

13 associations (top):

Study	Trait	p-value
GCST002325_1	Memory performance	6.000000e-08
GCST004751_1	Serum uric acid levels in response to allopurinol in gout	1.000000e-08
GCST005232_156	Neuroticism	2.000000e-14
GCST006940_154	Neurociticism	7.000000e-13
GCST006952_11	Feeling tense	5.000000e-08
GCST007709_114	General factor of neuroticism	4.000000e-09
GCST009028_1	Adverse response to drug	4.000000e-08
GCST010141_7	Beef consumption	4.000000e-08
GCST010347_1	Breast cancer	3.000000e-07
GCST010796_2855	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-08
GCST010988_69	Adult body size	1.000000e-08
GCST010989_277	Body size at age 10	9.000000e-09
GCST011494_76	Daytime nap	3.000000e-17

EFO canonical traits (9, from GWAS)

EFO ID	Trait name
EFO:0004874	memory performance
EFO:0004761	uric acid measurement
EFO:0007660	neuroticism measurement
EFO:0009596	feeling tense measurement
EFO:0009658	adverse effect
EFO:0008111	diet measurement
EFO:0004327	electrocardiography
EFO:0009819	comparative body size at age 10, self-reported
EFO:0007828	daytime rest measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

61 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
(+)-JQ1 compound	increases expression	3
Benzo(a)pyrene	affects methylation, decreases expression, increases methylation	3
bisphenol A	affects expression, affects cotreatment, increases methylation	2
Air Pollutants	affects cotreatment, increases abundance, increases oxidation, increases expression	2
Smoke	increases abundance, increases expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
Valproic Acid	increases expression, increases methylation	2
Particulate Matter	increases abundance, increases expression, decreases expression, affects cotreatment	2
aristolochic acid I	increases expression	1
FR900359	affects phosphorylation	1
triphenyl phosphate	affects expression	1
alpha-pinene	increases oxidation, increases abundance, affects cotreatment	1
quercitrin	affects expression	1
trichostatin A	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	increases expression	1
cobaltous chloride	increases expression	1
butyraldehyde	increases expression	1
perfluorooctanoic acid	decreases expression	1
manganese chloride	increases abundance, increases expression	1
coumarin	affects phosphorylation	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
ICG 001	decreases expression	1
abrine	increases expression	1
licochalcone B	increases expression	1
jinfukang	increases expression	1
LDN 193189	affects cotreatment, increases expression	1
PCI 5002	affects cotreatment, increases expression	1

Cellosaurus cell lines

5 cell lines: 5 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E1RM	HAP1 BAIAP2 (-) 1	Cancer cell line	Male
CVCL_E1RN	HAP1 BAIAP2 (-) 2	Cancer cell line	Male
CVCL_E1RP	HAP1 BAIAP2 (-) 3	Cancer cell line	Male
CVCL_E1RQ	HAP1 BAIAP2 (-) 4	Cancer cell line	Male
CVCL_E1RR	HAP1 BAIAP2 (-) 5	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00152750	PHASE4	UNKNOWN	Study of Clonidine on Sleep Architecture in Children With Tourette’s Syndrome (TS) and Comorbid ADHD
NCT00181571	PHASE4	COMPLETED	A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder
NCT00181675	PHASE4	COMPLETED	A Double-Blind Comparison of Galantamine HBr and Placebo in Adults With Attention Deficit Hyperactivity Disorder
NCT00181714	PHASE4	COMPLETED	Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta
NCT00181948	PHASE4	COMPLETED	Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy
NCT00181987	PHASE4	COMPLETED	Concerta in the Treatment of ADHD in Youth and Adults With Bipolar Disorder
NCT00190736	PHASE4	COMPLETED	Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)
NCT00190775	PHASE4	COMPLETED	A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00190879	PHASE4	COMPLETED	Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder
NCT00190957	PHASE4	COMPLETED	Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse
NCT00191035	PHASE4	COMPLETED	Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD
NCT00191048	PHASE4	COMPLETED	Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD
NCT00191633	PHASE4	COMPLETED	Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes
NCT00191906	PHASE4	COMPLETED	Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)
NCT00216918	PHASE4	COMPLETED	Neuropsychological Functioning in Children With Attention-Deficit/Hyperactivity Disorder.
NCT00221962	PHASE4	COMPLETED	Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)
NCT00223561	PHASE4	COMPLETED	Methylphenidate and Driving Ability in Adult Patients With Attention-Deficit Hyperactivity Disorder
NCT00299234	PHASE4	TERMINATED	Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL
NCT00302406	PHASE4	COMPLETED	Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate
NCT00305370	PHASE4	COMPLETED	Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD
NCT00381758	PHASE4	COMPLETED	The COMACS Study: A Comparison of Methylphenidates in an Analog Classroom Setting
NCT00406354	PHASE4	COMPLETED	Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany
NCT00434213	PHASE4	COMPLETED	Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA
NCT00468143	PHASE4	COMPLETED	A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall
NCT00471354	PHASE4	COMPLETED	A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine
NCT00483106	PHASE4	COMPLETED	Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)
NCT00485849	PHASE4	COMPLETED	A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD
NCT00485875	PHASE4	COMPLETED	Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD
NCT00486122	PHASE4	COMPLETED	Evaluation of Continuous Symptom Treatment of ADHD
NCT00500071	PHASE4	COMPLETED	Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD
NCT00506727	PHASE4	COMPLETED	Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD
NCT00510276	PHASE4	COMPLETED	Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes
NCT00517504	PHASE4	COMPLETED	Methylphenidate Study in Young Children With Developmental Disorders
NCT00517647	PHASE4	COMPLETED	Atomoxetine Pilot Study in Preschool Children With ADHD
NCT00518232	PHASE4	COMPLETED	A Study to Determine Effective and Tolerable Titration Scheme for OROS-Methylphenidate in Children With Attention-deficit Hyperactivity Disorder
NCT00530257	PHASE4	COMPLETED	Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory
NCT00536419	PHASE4	UNKNOWN	Impact of Attention Deficit/Hyperactivity Disorder and Substance Use Disorder on Motorcycle Traffic Accidents
NCT00546910	PHASE4	COMPLETED	Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00552266	PHASE4	UNKNOWN	Methylphenidate in ADHD With Trichotillomania
NCT00564954	PHASE4	COMPLETED	A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)